Hot stocks, November 2026

Research view: more likely to lag the S&P 500. Note of 14 November 2026: Rising Dragon Acquisition Corp., a blank-check company with no operating business, is more likely to lag the S&P 500 over three months: its HZJL merger ended on 30 October 2026 and no new target is named.

Research view: more likely to lag the S&P 500. XChange TEC.INC's shares trade on an AI-expansion plan with no disclosed First Cycle terms or US spending detail, so they are more likely to lag the S&P 500 over three months; a definitive agreement or the fiscal 2026 annual report settles it.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: AudioEye's shares are more likely to lag the S&P 500: the company is profitable, but sales grew 7%, the executive chairman kept selling, and the stock is up 137% in three months; the Q4 report decides it.

Note of 12 November 2026: Replimune's melanoma drug TUDRIQEV, first delivered on 6 October 2026, gives the shares a modest edge over the S&P 500 as early prescribing builds.

Research view: more likely to lead the S&P 500. Note of 12 November 2026: Telos Corporation's third-quarter beat and raised 2026 outlook, led by Telos ID and TSA PreCheck volumes, make the shares modestly more likely than not to beat the S&P 500.

Research view: more likely to lead the S&P 500. Note of 15 November 2026: Xeris Biopharma's shares are modestly more likely than not to beat the S&P 500 over three months because Recorlev sales rose 93% to $71.5 million in the third quarter and 2026 revenue guidance rose to $395–405 million.

Note of 12 November 2026: Grid Dynamics' AI work is lifting the IT-services firm back toward double-digit growth at margins near 20%, which favors the shares beating the S&P 500.

Note of 12 November 2026: Onterris's shares trade on a board-led strategic review that has engaged outside buyers and on a third-quarter cash flow recovery; a review outcome and fourth-quarter operating cash flow against the $30.0M–$40.0M guide settle the case.

Research view: more likely to lead the S&P 500. Note of 15 November 2026: Liquidia Corporation's shares are modestly more likely to beat the S&P 500 because YUTREPIA sales rose 31% to $222.7 million in the third quarter with record October shipments; preliminary fourth-quarter sales, due in early January 2027, show whether that holds as PH-ILD use winds down.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: ChargePoint shares are more likely to lag the S&P 500 after a 102% three-month rally that outran a business guiding third-quarter revenue below its second quarter.

Research view: more likely to lead the S&P 500. Note of 15 November 2026: Viridian Therapeutics' shares are modestly more likely than not to beat the S&P 500: Lumvoa's $24.7 million first full quarter beat estimates and VRDN-008 data on 9 November 2026 added an autoimmune program.

Note of 12 November 2026: Axogen's nerve-repair revenue grew 26.2% last quarter and a $754 million prostate market sits outside guidance, giving the shares a modest edge over the S&P 500; the Q4 2026 report settles whether revenue excluding BioCircuit reaches the…

Note of 12 November 2026: Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding into 2029.

Note of 12 November 2026: Upbound Group's tighter Acima lending is lifting profit and cash flow as lease volume shrinks, Brigit adds growth, and executives kept buying stock; the late-February 2027 Q4 report shows whether Acima volume levels off as guided.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: Frontier Group Holdings (Frontier Airlines) shares are more likely to lag the S&P 500: a $7.70 close on 12 November 2026 sits above most post-report targets as officers sold stock.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: DMC Global's shares look more likely to lag the S&P 500 than lead it: the fourth-quarter guide steps down and the $187.1 million Arcadia minority put is still open, despite a real cost-cut recovery.

Note of 12 November 2026: Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million, giving the shares a modest edge on a $1 billion 2027 outlook.

Note of 12 November 2026: Teladoc Health's Q3 2026 beat and fast-growing BetterHelp insurance revenue give the shares a modest edge over the S&P 500. The refinancing of $1.0 billion of notes due June 2027 and the Q4 report settle whether the turnaround holds.

Note of 12 November 2026: AppLovin's third-quarter 2026 revenue rose 55% to $2.185 billion and put growth back on track. The fourth-quarter report, expected around February 2027, shows whether its partly rolled-out ad models hold growth above the guided 43–44%.

Note of 12 November 2026: Ardent Health's cost-led hospital turnaround is running ahead of plan, with 2026 adjusted EBITDA guidance raised to $500–$535 million and Guggenheim and Stephens targets at $21; the 2027 outlook due with year-end results settles whether…

Research view: more likely to lag the S&P 500. Gogo's Galileo satellite service is growing fast and its loan now runs to 2030, but business aviation revenue fell 10% in the third quarter, so the shares are more likely to lag the S&P 500; the fourth-quarter report, expected around March 2027, settles it.

Research view: more likely to lead the S&P 500. TrueBlue's staffing recovery is in reported results (third-quarter revenue $520.7 million, fourth-quarter outlook $499–519 million), so the shares are more likely to lead the S&P 500 over three months; the late-February 2027 report tests gross margin.

Research view: more likely to lag the S&P 500. Better Home & Finance shares are more likely to lag the S&P 500 over three months: volume fell from $496 million in July to $345 million in October and cash is shrinking.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: OrthoPediatrics shares are more likely to lag the S&P 500 because the $33.67 close on 11 November 2026 sits above six of seven post-report analyst targets despite 19% sales growth.

Note of 12 November 2026: Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200 million buyback.

Research view: more likely to lead the S&P 500. Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely in 61% of high-dose patients against 0% on placebo, and the December 2026 52-week EVERLAST-A data show whether that clearance lasts a year without further dosing.

Note of 12 November 2026: Entravision's ad-technology unit grew 133% in the third quarter, beating its own guide, and the shares have held the gain; the fourth-quarter report in early 2027 settles whether ATS growth stays above 100%.

Research view: more likely to lead the S&P 500. Note of 12 November 2026: Firefly Aerospace's third-quarter beat, raised revenue floor and record $1.7 billion backlog make its shares modestly likely to beat the S&P 500; the fourth-quarter Alpha Block II debut settles whether launches carry the $440–450 million 2026 guide.

Research view: more likely to lead the S&P 500. Note of 12 November 2026: Portillo's turned same-restaurant sales positive and raised adjusted EBITDA guidance to $98–$101 million on 5 November 2026, leaving the shares modestly likelier than not to beat the S&P 500.

Note of 15 November 2026: Disc Medicine's shares are modestly favoured to beat the S&P 500 over three months because bitopertin passed its Phase 3 APOLLO trial on 19 October 2026, answering the FDA's February rejection.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: Hayward Holdings' raised 2026 guidance is already priced into shares trading above most broker targets, so they are more likely to lag the S&P 500; the late-February 2027 fourth-quarter report shows whether early-buy orders become sales.

Research view: more likely to lag the S&P 500. Note of 11 November 2026: Ultralife Corporation trades as a capped claim on EnerSys's $16.00-per-share cash offer, so it is more likely to lag the S&P 500 than lead it; US and UK clearances and the tender, first due to expire on 3 December 2026, settle whether holders are paid.

Research view: more likely to lag the S&P 500. Note of 14 November 2026: Silence Therapeutics' shares trade just under Merck KGaA's $20-per-ADS cash takeover price, so they are more likely to lag the S&P 500 than lead it over three months.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: Surgery Partners' shares, at $26.58 on 12 November 2026, already price in more than HealthSpan Partners' $25.00 cash deal pays and are more likely to lag the S&P 500.

Note of 12 November 2026: EVgo's shares track majority owner LS Power's $2.00-per-share cash take-private offer and closed at $1.75 on 12 November 2026, below it.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P 500 than lead it over three months.

Research view: more likely to lag the S&P 500. Note of 12 November 2026: ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead it.